





# RECEIVED

MAR 2 2 7002

DKT. 30435.54USDIEGHACENTER 1600/2300

## <u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

**Applicants** 

Robert Reiter, et al.

Serial No.

09/934,773

Examiner

Larry Helms

Filed

August 21, 2001

Group Art Unit:

1642

For

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

35 No. Arroyo Parkway Pasadena, California 91103 February 13, 2002

Honorable Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

# PETITION TO MAKE SPECIAL UNDER 37 CFR §1.102(d) and MPEP §708.02(X)

Applicants submit this Petition to Make Special under 37 CFR §1.102(d) and MPEP §708.02(X) to request that the U.S. Patent Office expedite examination of the above-identified patent application. Applicants contend that expedited examination of the subject application will advance the field of treating and preventing cancer and related diseases.

The subject application qualifies for expedited examination under 37 CFR §1.102(d) and MPEP §708.02(X) because the subject application provides novel compositions for treating and/or preventing cancers associated with PSCA, e.g. prostate cancer or cancers related thereof such as bone cancer metastasized from prostate cancer. The composition of the invention is directed to antibodies that bind a Prostate Stem Cell Antigen (PSCA) protein which is over-expressed as a cell-surface antigen in said cancers. The anti-PSCA antibodies are used to inhibit the growth of cancer cells expressing PSCA proteins, so as to

Applicants: Robert Reiter, et al. U.S. Serial No.: 09/934,773

Filed: August 21, 2001

Page: 2

fight diseases of or related to cancer. Thus, the anti-PSCA antibodies contribute an important new tool in developing effective treatments for, e.g., prostate cancer and related diseases. Accordingly, Applicants respectfully request that the subject application be accorded "special" status and its examination be expedited.

### CONCLUSION

In view of the foregoing remarks, Applicants respectfully request that pursuant to 37 CFR § 1.102(d) and M.P.E.P. § 708.02(X), the subject application be accorded "special" status and its prosecution be expedited. The fee for submitting a Petition to Make Special under 37 CFR 1.17(h) is \$130.00. Applicants enclose a check for the amount of \$130.00. If any additional fee is necessary, the Patent Office is authorized to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Registration No. 34,470

Roberta D. German

Registration No. 43,902

Attorneys for Applicants

Mandel & Adriano

35 N. Arroyo Parkway

Pasadena, California 91103

(626) 395-7801

Customer No: 26,941



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED where E. Reiter et al. 1/934,773 gust 21 200.

**Applicants:** 

Robert E. Reiter et al.

Serial No.:

09/934,773

Filed:

August 21, 2001

Docket:

30435.54USD3

Title:

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

### **CERTIFICATE UNDER 37 CFR 1.8**

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 13, 2002.

> COPY OF PAPERS ORIGINALLY FILED

35 N. Arroyo Parkway, Suite 60 Pasadena, California 91103 February 13, 2002

TECH CENTER 1600/2900

**BOX PATENT APPLICATION** Assistant Commissioner for Patents Washington, D.C. 20231

We are transmitting herewith the attached:

Transmittal sheet in duplicate, containing Certificate under 37 CFR §1.8.

Petition to Make Special Under 37 CFR§1.02(d) and MPEP §708.02(X.)

A check in the amount of \$130.00 to cover the filing fee.

Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 No. Arroyo Parkway, Suite 60 Pasadena, California 91103 (626)395-7801

Name: Sarah B. Adriano Reg. No.: 34,470 Customer No. 26,941